The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
 
Tara L. Lin
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Celgene (Inst); Celyad (Inst); CicloMed (Inst); Cleave Biosciences (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); incyte (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); Seagen (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst)
 
Robyn Wood
No Relationships to Disclose
 
Tammy Ham
Leadership - CicloMed
 
Taegen Sullivan
No Relationships to Disclose
 
Sangita Bhattacharyya
No Relationships to Disclose
 
Prasad Dandawate
No Relationships to Disclose
 
Shrikant Anant
No Relationships to Disclose
 
Marianne T Santaguida
No Relationships to Disclose
 
Na Zhang
No Relationships to Disclose
 
Paul Toren
No Relationships to Disclose
 
Roy A. Jensen
No Relationships to Disclose
 
John A. Taylor
Honoraria - ASCO
Consulting or Advisory Role - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - PCT/US11/21721. Use of Isoxazoline compounds and compositions in bladder cancer. Inventors: Taylor JA and Sielecki TM
Other Relationship - Photocure
 
Michael Jay Baltezor
Employment - CritiTech
Leadership - CritiTech
Stock and Other Ownership Interests - CritiTech
Consulting or Advisory Role - CicloMed
Patents, Royalties, Other Intellectual Property - Inventor on multiple patents that are pending and granted for CritiTech, Inc.
Travel, Accommodations, Expenses - CritiTech
 
Michael Dalton
No Relationships to Disclose
 
John McBride
No Relationships to Disclose
 
Jay Nicholas Umbreit
No Relationships to Disclose
 
William McCulloch
Employment - 3-V Biosciences; CicloMed; Ribon Therapeutics; Sagimet Biosciences
Leadership - 3-V Biosciences; Sagimet Biosciences
Stock and Other Ownership Interests - 3-V Biosciences; Sagimet Biosciences
Consulting or Advisory Role - CicloMed; Idera; Ribon Therapeutics
Patents, Royalties, Other Intellectual Property - Issued patents relating to romidepsin (Istodax(R)) assigned to Celgene, Inc. No financial interest.
Travel, Accommodations, Expenses - CicloMed; Ribon Therapeutics
 
Kathryn Vanderlaag
No Relationships to Disclose
 
Joseph Wagner
No Relationships to Disclose
 
Scott James Weir
Research Funding - CicloMed (Inst)
Patents, Royalties, Other Intellectual Property - Co-Inventor on issued Ciclopirox Prodrug composition-of-matter and methods-of-use patents
(OPTIONAL) Uncompensated Relationships - CicloMed